GV has joined the investors in oncology treatment developer Relay Therapeutics, which has now raised $120m altogether.

US-based cancer therapy developer Relay Therapeutics closed a $63m series B round yesterday featuring GV, an early-stage investment vehicle for internet technology group Alphabet.

The round was led by investment firm BVF Partners and included Alexandria Venture Investments, a division of life science real estate developer Alexandria Real Estate Equities, as well as Third Rock Ventures, Casdin Capital, EcoR1 Capital and Section 32.

Relay Therapeutics is creating a drug discovery platform that relies on insights into protein motion, making it possible…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?